 |
|
|
 |
Angry Young Men Prone To Premature Heart Disease
Young men who quickly react to stress with anger are at three times the normal risk of developing premature heart disease, according to a Johns Hopkins study of more than 1,000 physicians. more
|
|
Ginkgo Biloba Slows Cognitive Decline In Patients With Multiple Sclerosis
Ginkgo biloba, an over-the-counter herbal remedy used by many to boost mental awareness, has been shown in a medically supervised study to slow cognitive decline in patients with multiple sclerosis (MS), a chronic, often disabling disease that attacks the central nervous system. more
|
|
|
|
Significant Deficits In Mental Skills Observed In Toddlers Exposed To Cocaine Before Birth
A study conducted by researchers from Case Western Reserve University in Cleveland found that children exposed to cocaine before birth were twice as likely to have significant delays in mental skills by age 2, compared to other toddlers with similar backgrounds but whose mothers had not used cocaine during pregnancy. It is probable, according to the researchers, that these cocaine-exposed children will continue to have learning difficulties and an increased need for special educational services when they reach school age. more
|
|
Oxaliplatin Combo May Be Better Treatment For Advanced Colorectal Cancer
Patients with advanced (metastatic) colorectal cancer who received a multidrug regimen containing the investigational agent oxaliplatin appear to have fared significantly better than patients who received the current standard treatment, according to preliminary data from a randomized, Phase III clinical trial sponsored by the National Cancer Institute (NCI). more
|
|
FDA Approves Botox To Treat Frown Lines
On April 15, 2002, the FDA announced the approval of Botulinum Toxin Type A (Botox Cosmetic) to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines), a medical condition that is not serious. The product's manufacturer, Allergan, Inc., Irvine, California, is now allowed to market Botulinum Toxin Type A for this new indication. more
|
|
|
